BioSpace3h
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Business Insider8h
BridgeBio Pharma Receives Buy Rating Following Attruby’s FDA Approval and Strategic Milestones
Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...
ETF Daily News13h
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby™ (acoramidis)’
Notably, in the study, Attruby showed the most rapid benefits seen in any Phase 3 study of ATTR-CM to date, with significant ...
Alnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM Market
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
BridgeBio's Attruby (Acoramidis) Approval Could Pave Way for Long-Term Profitability
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...